ACRV
Acrivon Therapeutics, Inc. Common Stock NASDAQ Listed Nov 15, 2022$2.04
Pre-mkt
$1.89
-0.13%
Mkt Cap $64.2M
52w Low $1.05
39.2% of range
52w High $3.56
50d MA $1.68
200d MA $1.81
P/E (TTM)
-1.0x
EV/EBITDA
-0.7x
P/B
0.7x
Debt/Equity
0.0x
ROE
-69.2%
P/FCF
-1.4x
RSI (14)
—
ATR (14)
—
Beta
1.74
50d MA
$1.68
200d MA
$1.81
Avg Volume
833.9K
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
480 Arsenal Way · Watertown, MA 02472 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.49 | -0.49 | +0.0% | 1.70 | -0.6% | -2.4% | -3.6% | -1.2% | -3.8% | -6.6% | — |
| Nov 13, 2025 | AMC | -0.57 | -0.47 | +17.5% | 2.07 | -2.9% | +8.2% | +6.2% | +2.1% | -2.9% | -4.2% | — |
| Aug 13, 2025 | AMC | -0.57 | -0.55 | +3.5% | 1.31 | +4.6% | +6.1% | -2.9% | +3.0% | -6.5% | +0.0% | — |
| May 14, 2025 | AMC | -0.57 | -0.51 | +10.5% | 1.14 | +0.0% | -3.5% | +4.5% | +2.6% | +5.9% | -8.0% | — |
| Mar 27, 2025 | AMC | -0.69 | -0.60 | +13.0% | 2.52 | -1.6% | -11.1% | -9.4% | -17.2% | +3.6% | -5.7% | — |
| Nov 13, 2024 | AMC | -0.56 | -0.59 | -5.4% | 7.93 | +0.3% | -0.1% | -12.1% | -9.9% | +1.8% | +1.9% | — |
| Aug 13, 2024 | AMC | -0.59 | -0.52 | +11.9% | 7.25 | +1.4% | -3.2% | +3.0% | +5.1% | +9.6% | +8.4% | — |
| May 14, 2024 | AMC | -0.89 | -0.73 | +18.0% | 8.36 | +2.6% | +3.5% | -1.0% | +3.9% | -3.8% | -4.0% | — |
| Mar 28, 2024 | AMC | -0.72 | -0.86 | -19.4% | 7.15 | -0.8% | +1.4% | -7.7% | -0.4% | +0.5% | -3.1% | — |
| Nov 9, 2023 | AMC | -0.72 | -0.66 | +8.3% | 4.59 | +4.4% | -4.7% | +4.2% | +11.4% | +2.2% | -14.5% | — |
| Aug 11, 2023 | AMC | -0.68 | -0.63 | +7.4% | 12.39 | -2.3% | -3.1% | -2.4% | -3.9% | -2.0% | +0.8% | — |
| May 9, 2023 | AMC | -0.60 | -0.58 | +3.3% | 13.57 | +4.1% | -4.2% | +4.5% | -1.0% | +4.8% | -1.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 9 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.93 | $1.95 | +1.0% | -9.3% | -6.9% | +4.3% | +7.6% | +2.2% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.36 | $2.37 | +0.4% | -1.7% | +1.7% | +0.0% | +2.5% | -9.1% |
| Aug 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.31 | $1.37 | +4.6% | +6.1% | -2.9% | +3.0% | -6.5% | +0.0% |
| May 16 | Jones Trading | Downgrade | Buy → Hold | — | $1.10 | $1.12 | +1.8% | +4.5% | +2.6% | +5.9% | -8.0% | +0.0% |
| May 15 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.14 | $1.14 | +0.0% | -3.5% | +4.5% | +2.6% | +5.9% | -8.0% |
| Mar 28 | Oppenheimer | Maintains | Outperform → Outperform | — | $2.52 | $2.48 | -1.6% | -11.1% | -9.4% | -17.2% | +3.6% | -5.7% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.52 | $2.48 | -1.6% | -11.1% | -9.4% | -17.2% | +3.6% | -5.7% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.39 | $4.26 | -21.0% | -51.6% | -3.4% | -11.1% | -9.4% | -17.2% |
| Mar 26 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $5.39 | $4.26 | -21.0% | -51.6% | -3.4% | -11.1% | -9.4% | -17.2% |
| Mar 26 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $5.39 | $4.26 | -21.0% | -51.6% | -3.4% | -11.1% | -9.4% | -17.2% |
| Nov 14 | BMO Capital | Maintains | Outperform → Outperform | — | $7.93 | $7.95 | +0.3% | -0.1% | -12.1% | -9.9% | +1.8% | +1.9% |
| Nov 14 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $7.93 | $7.95 | +0.3% | -0.1% | -12.1% | -9.9% | +1.8% | +1.9% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.93 | $7.95 | +0.3% | -0.1% | -12.1% | -9.9% | +1.8% | +1.9% |
| Sep 16 | BMO Capital | Maintains | Outperform → Outperform | — | $8.91 | $9.50 | +6.6% | -7.6% | -7.7% | -0.5% | +0.4% | -1.6% |
| Sep 16 | Ladenburg Thalmann | Upgrade | Neutral → Buy | — | $8.91 | $9.50 | +6.6% | -7.6% | -7.7% | -0.5% | +0.4% | -1.6% |
| Sep 16 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $8.91 | $9.50 | +6.6% | -7.6% | -7.7% | -0.5% | +0.4% | -1.6% |
| Sep 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.91 | $9.50 | +6.6% | -7.6% | -7.7% | -0.5% | +0.4% | -1.6% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.59 | $7.66 | +0.9% | -4.5% | -3.2% | +3.0% | +5.1% | +9.6% |
| May 15 | BMO Capital | Maintains | Outperform → Outperform | — | $8.36 | $8.58 | +2.6% | +3.5% | -1.0% | +3.9% | -3.8% | -4.0% |
| May 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.48 | $8.32 | -1.9% | -1.4% | +3.5% | -1.0% | +3.9% | -3.8% |
| Apr 29 | Ladenburg Thalmann | Downgrade | Buy → Neutral | — | $8.46 | $8.22 | -2.8% | +18.2% | -9.1% | -9.5% | +2.8% | +13.4% |
| Apr 26 | BMO Capital | Maintains | Outperform → Outperform | — | $8.47 | $8.53 | +0.7% | -0.1% | +18.2% | -9.1% | -9.5% | +2.8% |
| Apr 25 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $9.50 | $9.50 | +0.0% | -10.8% | -0.1% | +18.2% | -9.1% | -9.5% |
| Apr 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.50 | $9.50 | +0.0% | -10.8% | -0.1% | +18.2% | -9.1% | -9.5% |
| Apr 25 | Piper Sandler | Maintains | Overweight → Overweight | — | $9.50 | $9.50 | +0.0% | -10.8% | -0.1% | +18.2% | -9.1% | -9.5% |
| Apr 5 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $6.69 | $6.57 | -1.8% | -3.1% | -8.8% | +62.8% | +8.0% | -10.6% |
| Apr 1 | BMO Capital | Maintains | Outperform → Outperform | — | $7.15 | $7.09 | -0.8% | +1.4% | -7.7% | -0.4% | +0.5% | -3.1% |
| Apr 1 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $7.15 | $7.09 | -0.8% | +1.4% | -7.7% | -0.4% | +0.5% | -3.1% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.47 | $6.29 | -2.8% | +10.5% | +1.4% | -7.7% | -0.4% | +0.5% |
| Nov 10 | BMO Capital | Maintains | Outperform → Outperform | — | $4.59 | $4.79 | +4.4% | -4.7% | +4.2% | +11.4% | +2.2% | -14.5% |
| Sep 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.10 | $12.09 | -0.1% | -1.7% | -1.7% | -1.7% | +0.8% | -4.8% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.60 | $11.60 | +0.0% | +6.8% | -3.1% | -2.4% | -3.9% | -2.0% |
No insider trades available.
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
This boilerplate 8-K disclosure safeguards ACRV from liability for voluntary information sharing, but provides no material news about business performance or strategy changes affecting stock valuation.
Mar 19
8-K
Acrivon Therapeutics, Inc. -- 8-K Filing
Acrivon terminated its diagnostic partnership with Quanterix but secured continued clinical testing support during transition to Acrivon's CLIA laboratory for its ACR-368 oncology study.
Mar 2
8-K · 7.01
! Medium
Acrivon Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Acrivon Therapeutics disclosed positive interim ACR-368 clinical data for endometrial cancer treatment at a key opinion leader panel, supporting the drug's potential to address unmet serous subtype needs.
Feb 27
Data updated apr 24, 2026 10:42am
· Source: massive.com